1551 Eastlake Ave E
129 articles with Adaptive Biotechnologies
Job hunting can be a challenging time for people. Finding open positions that fit your skill set and then competing with other highly-qualified people can be bruising, especially if you’re already a bit damaged from a recent layoff.
Rigel Pharmaceuticals, Inc. today announced that it has appointed Dean Schorno, CPA as Executive Vice President and Chief Financial Officer (CFO).
Adaptive Biotechnologies Announces a Collaboration with Sanofi to Use Adaptive’s clonoSEQ® Assay to Measure Minimal Residual Disease in Active and Future Isatuximab Multiple Myeloma Trials
Adaptive Biotechnologies announced today that it entered into an agreement with Sanofi to utilize Adaptive’s NGS-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to isatuximab.
This new indication marks the first time the FDA has approved a therapy based on MRD status.
Adaptive Biotechnologies Appoints Veteran Molecular Diagnostics Executive Michael Pellini, MD, to Board of Directors
As the former CEO and current Chairman of the Board of Directors of Foundation Medicine, Dr. Pellini led the development and commercialization of a suite of molecular information products and services to aid in the diagnosis and management of advanced cancer, and to optimize the discovery and development of novel oncology therapies.
Adaptive Biotechnologies Announces Partnership with Microsoft to Decode the Human Immune System to Improve the Diagnosis of Disease
Adaptive Biotechnologies announced today their partnership with Microsoft to map the genetics of the human immune system, or immunome, in order to detect cancers and other diseases in their earliest stage, when they can be more effectively treated.
Adaptive Biotechnologies and Collaborators to Highlight Clinical Relevance of Measuring Residual Disease in Blood Cancers at ASH 2017
Data presented at ASH will demonstrate how Adaptive’s clonoSEQ Assay to measure MRD, the cancerous cells remaining in the body after treatment, can inform clinical care in patients with B and T cell lymphoid malignancies.
Adaptive Biotechnologies Announces a Collaboration with Amgen to Advance Clinical Development of the clonoSEQ Assay in Multiple Myeloma
Adaptive Biotechnologies announces it has entered into a collaboration agreement with Amgen to utilize Adaptive’s NGS-based clonoSEQ Assay in the Phase 3 CANDOR study.
Adaptive Biotech Expands Leadership To Bolster Integration Of Immune Profiling Into Clinical Care Setting
Adaptive Biotech Announces A Collaboration With Janssen Biotech To Use The clonoSEQ? Assay To Measure Minimal Residual Disease In Ongoing And Future DARZALEX? Multiple Myeloma Trials
Adaptive Biotech Announces A Collaboration With Janssen Biotech To Use The Clonoseq Assay To Measure Minimal Residual Disease In Ongoing And Future DARZALEX Multiple Myeloma Trials
Adaptive Biotech Announces A Collaboration With Amgen To Advance Development Of Clonoseq Assay In Acute Lymphoblastic Leukemia
Adaptive Biotech Announces The Inclusion Of NGS-Based MRD Assessment In The NCCN Clinical Practice Guidelines For Multiple Myeloma
Heat Biologics And Adaptive Biotech To Discover Potential Clinical Biomarkers To Advance Novel Immunotherapies
Adaptive Biotech Release: World’s Leading Experts To Discuss The Advances Of Immune Profiling In Health And Disease During Unparalleled Conference
Adaptive Biotech Provides Open-Access To The Deepest Immunosequencing Dataset Of Unique B-Cell Receptors (BCRs) For Immunology Research
Adaptive Biotech And Collaborators To Present Data Demonstrating High-Throughput Sequencing For Minimal Residual Disease (MRD) Is More Sensitive Than Flow Cytometry And Can Be Used As A Determinant Of Early Response To Therapy